These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18987645)

  • 1. Human interferon-lambda3 is a potent member of the type III interferon family.
    Dellgren C; Gad HH; Hamming OJ; Melchjorsen J; Hartmann R
    Genes Immun; 2009 Mar; 10(2):125-31. PubMed ID: 18987645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression.
    Santer DM; Minty GES; Mohamed A; Baldwin L; Bhat R; Joyce M; Egli A; Tyrrell DLJ; Houghton M
    J Immunol Methods; 2017 Jun; 445():15-22. PubMed ID: 28274837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity of bovine type III interferon against bovine viral diarrhea virus is greatly reduced in bovine turbinate cells due to limited expression of IFN lambda receptor 1 (IL-28Rα).
    Dassanayake RP; Menghwar H; Bickel KA; Holthausen DJ; Ma H; Diaz-San Segunda F; Rodriguez-Calzada M; Medina GN; Attreed S; Falkenberg SM; Kanipe C; Sacco RE; De Los Santos T; Casas E
    Front Immunol; 2024; 15():1441908. PubMed ID: 39224597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain.
    Donnelly RP; Sheikh F; Kotenko SV; Dickensheets H
    J Leukoc Biol; 2004 Aug; 76(2):314-21. PubMed ID: 15123776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets.
    Lind K; Richardson SJ; Leete P; Morgan NG; Korsgren O; Flodström-Tullberg M
    J Virol; 2013 Jul; 87(13):7646-54. PubMed ID: 23637411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.
    Lasfar A; Lewis-Antes A; Smirnov SV; Anantha S; Abushahba W; Tian B; Reuhl K; Dickensheets H; Sheikh F; Donnelly RP; Raveche E; Kotenko SV
    Cancer Res; 2006 Apr; 66(8):4468-77. PubMed ID: 16618774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza A virus replication is inhibited in IFN-λ2 and IFN-λ3 transfected or stimulated cells.
    Svetlikova D; Kabat P; Ohradanova A; Pastorek J; Betakova T
    Antiviral Res; 2010 Dec; 88(3):329-33. PubMed ID: 20969894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells.
    Santer DM; Minty GES; Golec DP; Lu J; May J; Namdar A; Shah J; Elahi S; Proud D; Joyce M; Tyrrell DL; Houghton M
    PLoS Pathog; 2020 Apr; 16(4):e1008515. PubMed ID: 32353085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29).
    Megjugorac NJ; Gallagher GE; Gallagher G
    J Leukoc Biol; 2009 Dec; 86(6):1359-63. PubMed ID: 19759281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family.
    Gad HH; Dellgren C; Hamming OJ; Vends S; Paludan SR; Hartmann R
    J Biol Chem; 2009 Jul; 284(31):20869-75. PubMed ID: 19457860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome.
    Apostolou E; Kapsogeorgou EK; Konsta OD; Giotakis I; Saridaki MI; Andreakos E; Tzioufas AG
    Clin Exp Immunol; 2016 Dec; 186(3):304-312. PubMed ID: 27613139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
    Kotenko SV; Gallagher G; Baurin VV; Lewis-Antes A; Shen M; Shah NK; Langer JA; Sheikh F; Dickensheets H; Donnelly RP
    Nat Immunol; 2003 Jan; 4(1):69-77. PubMed ID: 12483210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.
    Jordan WJ; Eskdale J; Srinivas S; Pekarek V; Kelner D; Rodia M; Gallagher G
    Genes Immun; 2007 Apr; 8(3):254-61. PubMed ID: 17361203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of canine interferon-lambda.
    Fan W; Xu L; Ren L; Qu H; Li J; Liang J; Liu W; Yang L; Luo T
    J Interferon Cytokine Res; 2014 Nov; 34(11):848-57. PubMed ID: 24950142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses.
    Li M; Liu X; Zhou Y; Su SB
    J Leukoc Biol; 2009 Jul; 86(1):23-32. PubMed ID: 19304895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-λ4 inhibits HIV infection of macrophages through signalling of IFN-λR1/IL-10R2 receptor complex.
    Su QJ; Wang X; Zhou RH; Guo L; Liu H; Li JL; Ho WZ
    Scand J Immunol; 2018 Nov; 88(5):e12717. PubMed ID: 30247785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and expression profiling of buffalo IFN-lambda family.
    Gautam D; Sindhu A; Vats A; Rajput S; Roshan M; Pal H; De S
    Vet Immunol Immunopathol; 2024 Jun; 272():110770. PubMed ID: 38735115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes.
    Yu D; Zhao M; Dong L; Zhao L; Zou M; Sun H; Zhang M; Liu H; Zou Z
    Drug Des Devel Ther; 2016; 10():163-82. PubMed ID: 26792983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection.
    Stoltz M; Klingström J
    J Virol; 2010 Sep; 84(18):9140-8. PubMed ID: 20592090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents.
    Li Q; Kawamura K; Ma G; Iwata F; Numasaki M; Suzuki N; Shimada H; Tagawa M
    Eur J Cancer; 2010 Jan; 46(1):180-90. PubMed ID: 19879751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.